95 related articles for article (PubMed ID: 12479856)
41. Urokinase plasminogen activator receptor (CD87): something old, something new.
Ge Y; Elghetany MT
Lab Hematol; 2003; 9(2):67-71. PubMed ID: 12828301
[TBL] [Abstract][Full Text] [Related]
42. [Establishment of urokinase receptor gene antisense RNA transfer system and its application in leukemia research].
Bai X; Fu JX; Xi XD; Ruan CG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):591-4. PubMed ID: 14706141
[TBL] [Abstract][Full Text] [Related]
43. In vitro sensitivity of hematopoietic progenitors to tiazofurin in refractory acute myeloid leukemia and in the blast crisis of chronic myeloid leukemia.
Colovic M; Sefer D; Bogdanovic A; Suvajdzic N; Jankovic G; Atkinson HD; Milenkovic P
Cancer Lett; 2003 Jun; 195(2):153-9. PubMed ID: 12767523
[TBL] [Abstract][Full Text] [Related]
44. CD117/CD34 expression in leukemic blasts.
Wells SJ; Bray RA; Stempora LL; Farhi DC
Am J Clin Pathol; 1996 Aug; 106(2):192-5. PubMed ID: 8712172
[TBL] [Abstract][Full Text] [Related]
45. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor.
Nadir Y; Katz T; Sarig G; Hoffman R; Oliven A; Rowe JM; Brenner B
Haematologica; 2005 Nov; 90(11):1549-56. PubMed ID: 16266903
[TBL] [Abstract][Full Text] [Related]
46. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein.
Alexander RL; Kucera GL; Klein B; Frankel AE
Bioconjug Chem; 2000; 11(4):564-8. PubMed ID: 10898579
[TBL] [Abstract][Full Text] [Related]
47. Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression.
Testa U; Riccioni R; Biffoni M; Diverio D; Lo-Coco F; Foà R; Peschle C; Frankel AE
Blood; 2005 Oct; 106(7):2527-9. PubMed ID: 15928038
[TBL] [Abstract][Full Text] [Related]
48. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.
Hogge DE; Yalcintepe L; Wong SH; Gerhard B; Frankel AE
Clin Cancer Res; 2006 Feb; 12(4):1284-91. PubMed ID: 16489085
[TBL] [Abstract][Full Text] [Related]
49. Variability in the expression of urokinase receptor (CD87) mutants on cells: relevance to cell adhesion.
Kanse SM; Chavakis T; Kuo A; Bdeir K; Cines DB; Preissner KT
Cell Biochem Funct; 2004; 22(4):257-64. PubMed ID: 15248186
[TBL] [Abstract][Full Text] [Related]
50. Urokinase plasminogen activator receptor (uPAR; CD87) expression on monocytic cells and T cells is modulated by HIV-1 infection.
Speth C; Pichler I; Stöckl G; Mair M; Dierich MP
Immunobiology; 1998 Jul; 199(1):152-62. PubMed ID: 9717675
[TBL] [Abstract][Full Text] [Related]
51. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
52. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes.
Sitrin RG; Todd RF; Albrecht E; Gyetko MR
J Clin Invest; 1996 Apr; 97(8):1942-51. PubMed ID: 8621779
[TBL] [Abstract][Full Text] [Related]
53. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor.
Bendel AE; Shao Y; Davies SM; Warman B; Yang CH; Waddick KG; Uckun FM; Perentesis JP
Leuk Lymphoma; 1997 Apr; 25(3-4):257-70. PubMed ID: 9168436
[TBL] [Abstract][Full Text] [Related]
54. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
55. Role of flow cytometry in multiple myeloma and the prognostic significance of CD87 (uPAR) expression.
Albayrak M; Şahin Balçık Ö; Dağdaş S; Yılmaz M; Ceran F; Yokuş O; Özet G
Turk J Haematol; 2010 Sep; 27(3):182-9. PubMed ID: 27263603
[TBL] [Abstract][Full Text] [Related]
56. Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death.
Horita H; Frankel AE; Thorburn A
Leukemia; 2008 Mar; 22(3):652-5. PubMed ID: 17882279
[No Abstract] [Full Text] [Related]
57. Effects of flt3 ligand on acute myeloid and lymphocytic leukemic blast cells from children.
McKenna HJ; Smith FO; Brasel K; Hirschstein D; Bernstein ID; Williams DE; Lyman SD
Exp Hematol; 1996 Feb; 24(2):378-85. PubMed ID: 8641369
[TBL] [Abstract][Full Text] [Related]
58. Prognostic significance of the blast self-renewal capacity in patients with acute myeloid leukemia.
Nara N; Kurokawa H; Tanikawa S; Tomiyama J; Nagata K
Cancer; 1994 Jan; 73(1):92-7. PubMed ID: 8275443
[TBL] [Abstract][Full Text] [Related]
59. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
60. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
Dash AB; Williams IR; Kutok JL; Tomasson MH; Anastasiadou E; Lindahl K; Li S; Van Etten RA; Borrow J; Housman D; Druker B; Gilliland DG
Proc Natl Acad Sci U S A; 2002 May; 99(11):7622-7. PubMed ID: 12032333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
